Mahamaya Lifesciences Ltd. (MAHALIFE) — Tipsheet https://tipsheet.markets/company/mahalife/ Every Tipsheet Editorial note covering Mahamaya Lifesciences Ltd. (MAHALIFE), newest first. Grounded in BSE/NSE primary-source filings. en-in Sat, 18 Jul 2026 05:18:54 GMT Mahamaya Lifesciences releases FY26 audited results https://tipsheet.markets/mahalife-mahamaya-lifesciences-releases-fy26-audited-results-98615/ https://tipsheet.markets/mahalife-mahamaya-lifesciences-releases-fy26-audited-results-98615/ Tue, 26 May 2026 13:14:55 GMT The company confirms previously disclosed annual figures of ₹328.87 crore in revenue and ₹16.52 crore in profit. The company confirms previously disclosed annual figures of ₹328.87 crore in revenue and ₹16.52 crore in profit.

What’s new

  • Mahamaya Lifesciences released its audited financial results for FY26.
  • The filing repeats revenue of ₹328.87 crore and profit of ₹16.52 crore.
  • The release provides management commentary but no new financial data.

Why it matters

This is a routine dissemination of previously reported numbers. Investors should treat this as a procedural update rather than a source of new information.

What we’re watching

  • Future operational updates or contract wins.
  • Any divergence from the previously disclosed annual figures.
  • Management's outlook for the coming fiscal year.

The full read

Mahamaya Lifesciences has released its audited financial results for FY26. The filing confirms annual revenue of ₹328.87 crore and a profit after tax of ₹16.52 crore.

These figures were already disclosed in a prior board meeting outcome. This release adds management commentary and operational context, but it contains no material new financial information for the company. For a nano-cap entity, this is a routine update that confirms the previously reported performance.

Nothing changed.

Primary source: BSE · NSE

]]> Earnings Tipsheet Editorial